Refracture following fracture liaison service assessment illustrates the requirement for integrated falls and fracture services

Calcif Tissue Int. 2007 Aug;81(2):85-91. doi: 10.1007/s00223-007-9042-0. Epub 2007 Jul 16.

Abstract

The Fracture Liaison Service (FLS) allows appropriate antiosteoporosis therapy to be targeted to potentially reduce future fracture risk. A proportion of these treated patients will still experience a further fracture. This work reviews the characteristics of these patients. Data were collated for patients >65 years old presenting to the South Glasgow FLS between January 2001 and August 2004. There were 2,489 patients who presented (incident fracture group), and 129 (5.2%) sustained an additional fracture (refracture group). Median age of the incident fracture group was 77.8 years vs. 80.6 years for the refracture group (P = nonsignificant). The refracture group was determined according to whether their incident fracture was hip (n = 47) or nonhip (n = 82). When the incident fracture was hip, a refracture was more likely to be a further hip fracture (chi(2) = 14.4, P = 0.002) and patients refractured sooner (median time to refracture 194 [range 10-1,134] days vs. 258 [range 6-1,081] days [nonhip]) (P = nonsignificant). In the refracture group, 76% of patients were already on osteoporosis treatment after their incident fracture. Patients over 65 years of age presenting to FLS who sustain an additional fracture are older; are likely to sustain another hip fracture after an incident hip fracture; often refracture early, particularly when the incident fracture is of the hip; and are often already on antiosteoporosis treatment. Therefore, it is important to identify these high-risk patients and offer a combined approach of prompt drug treatment through a systematic and specialist osteoporosis management team along with reducing any reversible falls risk factors.

MeSH terms

  • Accidental Falls / prevention & control*
  • Accidental Falls / statistics & numerical data
  • Age Distribution
  • Aged
  • Aged, 80 and over
  • Bone Density Conservation Agents / therapeutic use
  • Calcium / therapeutic use
  • Diphosphonates / therapeutic use
  • Female
  • Fractures, Bone / epidemiology*
  • Fractures, Bone / prevention & control*
  • Hip Fractures / epidemiology
  • Hip Fractures / prevention & control
  • Humans
  • Incidence
  • Male
  • Osteoporosis / drug therapy*
  • Osteoporosis / epidemiology*
  • Patient Care Team*
  • Quality of Health Care
  • Risk Factors
  • Scotland
  • Secondary Prevention
  • Vitamin D / therapeutic use

Substances

  • Bone Density Conservation Agents
  • Diphosphonates
  • Vitamin D
  • Calcium